Strengthening mucosal immunity could improve protection against respiratory infections

A review published in Genes & Diseases highlights how strengthening immunity in the nose and airways could improve protection against respiratory infections. Researchers at West China Hospital, Sichuan University, examine the respiratory mucosa as both a frontline defence system and a target for vaccines and inhalable antibody therapies.

The respiratory mucosa is the tissue lining the airways, where inhaled pathogens first encounter the body's defences. Its protective network combines physical barriers, mucus clearance, antimicrobial molecules, and immune cells. Crucially, it must eliminate harmful invaders while tolerating harmless substances and avoiding inflammation that damages lung tissue.

The review explains five functions: immune tolerance, barrier protection, immune surveillance, tissue repair, and long-term immune memory. Disruption of these processes can contribute to viral, bacterial, and fungal infections, as well as chronic inflammatory conditions such as asthma and chronic obstructive pulmonary disease.

A central focus is vaccination at the respiratory portal of entry. Intranasal and inhaled approaches aim to build local protection alongside systemic immunity. Secretory immunoglobulin A, an antibody found at mucosal surfaces, and tissue-resident memory T cells are important components of this defence, helping recognize pathogens and respond where infection begins.

The article surveys live-attenuated, inactivated, viral vector, protein subunit, and mRNA vaccine platforms. It also considers delivery technologies and immune-enhancing strategies designed to help vaccine components reach tissues and produce longer-lasting responses.

In parallel, inhalable antibodies offer a potential route to rapid local protection or early treatment. Delivering antibodies directly to airway surfaces could concentrate antiviral activity at infection sites. However, the review notes that promising antiviral findings have not always translated into clinical improvements, and formulation stability remains challenging.

The researchers outline three priorities for future vaccine design: strengthen immunity in the upper airways, broaden antigen coverage beyond narrowly matched strains, and establish intranasal safety. These priorities could support more durable protection and preparedness for emerging respiratory pathogens.

Important barriers remain. Airway anatomy, mucus, airflow, and rapid clearance can make delivery inconsistent between individuals. Immune responses may also fade, while stronger immune stimulation can increase local inflammation. Reliable measures that predict mucosal protection are still needed.

The review emphasizes that animal results do not guarantee effectiveness in humans. Better clinical studies, standardized sampling methods, and long-term monitoring will be essential to assess both protection and safety.

Source:
Journal reference:

Zhang, Y., et al. (2026) Respiratory mucosal immunity: Biological functions, diseases, prevention and therapy. Genes & Diseases. DOI: 10.1016/j.gendis.2026.102200. https://www.sciencedirect.com/science/article/pii/S2352304226001728?via%3Dihub

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Medical societies unify to endorse evidence-based respiratory vaccine guidance